Phase 1 Eczema Trial, Recruiting NCT07015762 Sponsor: The First Affiliated Hospital of Soochow University Condition: Eczema
Back to Eczema

Phase 1 Eczema Trial, Recruiting

NCT07015762
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You weigh at least 40kg (about 88 pounds)
  • You have been diagnosed with atopic dermatitis (a type of eczema) for at least 12 months before the screening visit, based on recognised medical criteria (previous diagnoses of "dermatitis" or "eczema" may also be accepted, as decided by the trial doctor)
  • Your eczema is assessed as moderate to severe, meaning it scores highly enough on three different medical measures of how widespread and serious it is at both the screening and start-of-trial visits (confirm with trial site)

Who may not be able to join:

  • You have a significant illness affecting your safety or ability to take part, such as a mental health condition or a condition affecting the heart, lungs, gut, kidneys, blood, brain, or metabolism, as judged by the trial doctor
  • You have a known history of active tuberculosis (TB), any signs that might suggest TB, a chest scan showing possible TB, or other evidence of a hidden TB infection — unless you are able to take preventive TB treatment starting 4 weeks before the trial begins and continuing until the end
  • You have a history of cancer, except for certain types of skin cancer (basal cell carcinoma or squamous cell carcinoma) that have been fully removed or cured
  • Your white blood cell count or neutrophil count (types of immune cells) is below the normal range at either the screening or start-of-trial visit
  • You have another skin condition that could make it difficult to assess your eczema accurately, as judged by the trial doctor

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 15210342569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
The First Affiliated Hospital of Soochow University
Registry
ClinicalTrials.gov
Start date
14 July 2025
Est. completion
20 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

To evaluate the safety and tolerability of multiple doses of IBI3002 in Atopic Dermatitis patients.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov